The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
11-Sep-24
$620 million
Target:
Mobileum, Inc.
Advised the Ad Hoc Crossover Group to Mobileum on its Chapter 11 Restructuring
09-Sep-24
Undisclosed
Target:
Pixelligent Technologies
Acquiror:
Henkel Corporation
Advised Pixelligent Technologies, a developer and manufacturer of nanocrystal material used in consumer electronic devices, on a significant strategic investment from Henkel Corporation, a publicly traded (FWB: HEN) German multinational chemical and consumer goods company
13-Aug-24
Undisclosed
Target:
U.S. Operations of NextStream
Acquiror:
RadiusDC
Advised RadiusDC, a national owner and operator of highly-connected, urban-located data centers, on the acquistion of a series of entities comprising the U.S. operations of NextStream, a data center operator in Latin America owned by Actis
29-Jul-24
Undisclosed
Target:
APA Corporation Midland Basin Minerals and Royalties Interests
Acquiror:
Post Oak Energy Capital, LP
Advised Post Oak Energy Capital, a Houston-based, energy-focused private equity firm, on the acquisition of Midland Basin Minerals and Royalties Assets from APA Corporation, an independent oil and gas producer
24-Jul-24
Undisclosed
Target:
INX Software
Acquiror:
Accel-KKR
Advised Tanarra Capital, leading diversified alternative asset investment firm in Australia, on its sale of INX Software, leading end-to-end workforce management and EHS software provider for high-risk, complex and remote businesses, to Accel-KKR
03-Jul-24
Pending
$183 million (Maximum Purchase Price)
Target:
Desktop Metal, Inc.
Acquiror:
Nano Dimension Ltd.
Advising Nano Dimension, a developer of 3D printing and Additive Manufacturing technologies, predominantly for A&D applications, on its acquisition of Desktop Metal, a vertically integrated 3D printers, materials and software company and pioneer of several 3D printing technologies
01-Jul-24
Undisclosed
Target:
Medical Review Institute of America
Acquiror:
Parthenon Capital
Advised Medical Review Institute of America, a portfolio company of Summit Partners and a leading provider of outsourced utilization management and clinical review solutions to payors, on its strategic growth investment from Parthenon Capital
26-Jun-24
Pending
$630 million
Target:
Haleon plc’s Nicotine Replacement Therapy Business (ex-US)
Acquiror:
Dr. Reddy’s Laboratories
Advising Haleon plc on the sale of its global nicotine replacement therapy business (ex-US) to Dr. Reddy’s Laboratories
24-Jun-24
$875 million
Target:
Durango Permian
Acquiror:
Kinetik Holdings
Advised Durango Midstream, an owner and operator of natural gas gathering & processing infrastructure, and Morgan Stanley Energy Partners (“MSEP”) on the sale of Durango Permian LLC to Kinetik Holdings Inc. (NYSE: KNTK), a premier midstream operator in the Delaware Basin
20-Jun-24
Pending
$1.8 billion
Target:
CP Kelco
Acquiror:
Tate & Lyle
Advising Tate & Lyle plc, a UK-listed specialty food and beverage ingredients company, on the acquisition of CP Kelco, a US-based provider of pectin, speciality gums and other nature-based ingredients, from J.M. Huber Corporation
08-May-24
$800 million
Target:
U.S. Acute Care Solutions
Advised U.S. Acute Care Solutions, the largest majority physician-owned emergency medicine practice in the United States, on the refinancing of its senior secured notes
01-May-24
Undisclosed
Target:
Functional Formularies
Acquiror:
Danone
Advised Danone on its acquisition of Functional Formularies, a leading whole foods tube feeding business in the US, from Swander Pace Capital
05-Feb-24
Pending
Undisclosed
Target:
Equity Interest in ARM Energy Trading
Acquiror:
Tokyo Gas America
Advising Tokyo Gas America on the acquisition of a 49% equity interest stake in ARM Energy Holding’s producer services and wholesale commodity trading business, ARM Energy Trading. Tokyo Gas America is an energy company that engages in a wide range of businesses, including operated gas and oil assets, midstream, downstream, power generation, natural gas distribution, and LNG exportation
15-Jan-24
Pending
$1.29 billion
Target:
QuarterNorth Energy Inc.
Acquiror:
Talos Energy Inc.
Advising Talos Energy, an independent exploration and production company, on the acquisition of QuarterNorth Energy, a privately held offshore Gulf of Mexico E&P operator with working interests in several prolific deepwater U.S. Gulf of Mexico assets
15-Dec-23
Pending
$2.7 billion
Target:
Rockcliff Energy II LLC
Acquiror:
TG Natural Resources
Advising TG Natural Resources on the acquisition of Rockcliff Energy II LLC, a portfolio company of Quantum Energy Partners (“Quantum”). Rockcliff is a premier natural gas company in the prolific East Texas Haynesville shale and one of the top natural gas producers in the state of Texas. TG Natural Resources is a Houston based, private E&P company with operations focused in the Haynesville Shale and majority owned by Tokyo Gas
13-Dec-23
Pending
Undisclosed
Target:
Vopak Moda Houston
Acquiror:
Exolum
Advising Exolum on its acquisition of 50% interest in Vopak Moda Houston, a leading ammonia and NGL storage & export terminal, from Moda Midstream (Encap Flatrock-Backed)
16-Nov-23
~$400 million
Target:
Sonoma-Cutrer Vineyards (Brown-Forman)
Acquiror:
The Duckhorn Portfolio
Advised Brown-Forman, the largest American-owned spirits and wine company, on its sale of Sonoma-Cutrer Vineyards to The Duckhorn Portfolio
14-Nov-23
Undisclosed
Target:
Minerals and Royalties Interest
Acquiror:
Undisclosed
Advised a company on the sale of its minerals and royalties interests in the Appalachian Basin
04-Oct-23
$610 million
Target:
Lucky Bucks, LLC
Advised the Term Loan Ad Hoc Group to Lucky Bucks, one of the largest Class B coin operated amusement machine (“COAM”) route operators in Georgia, on Lucky Bucks’ financial restructuring and chapter 11 process
27-Sep-23
Undisclosed
Target:
Slayback Pharma LLC
Acquiror:
Azurity Pharmaceuticals
Advised Azurity Pharmaceuticals, a pharmaceutical company specializing in the provision of innovative medicines to overlooked patients, on the acquisition of Slayback Pharma LLC ("Slayback"), a company focused on complex generic and specialty pharmaceutical products
14-Jul-23
$674 million
Target:
Juice Plus+
Advised Juice Plus+, a global health and wellness company in the direct selling space on a comprehensive recapitalization transaction
01-Jun-23
Pending
Undisclosed
Target:
Interest in Joint Venture with CarepathRx Health System Solutions
Acquiror:
The Cigna Group
Advising Cigna on its investment in CarepathRx Health System Solutions, under Evernorth, Cigna’s health services subsidiary
16-Feb-23
Pending
$220 million
Target:
Flavor Specialty Ingredients division of IFF
Acquiror:
Exponent Private Equity
Sole financial adviser to Exponent, one of the UK’s leading private equity firms, on the acquisition of IFF’s Flavor Specialty Ingredients division, a global leader in the base aromas market
10-Feb-23
Pending
$415 million
Target:
Gaming Services Division of Global Payments
Acquiror:
Parthenon Capital
Advising Parthenon Capital, a financial services & technology focused private equity firm, on its acquisition of Global Payment’s Gaming Services Division, a leading provider of on-site and digital payment processing services to companies in the gaming industry, for $415mm
23-Jan-23
Pending
$200 million
Target:
Clinigen Ltd’s Proleukin
Acquiror:
Iovance Biotherapeutics
Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Proleukin (Interleukin-2 (Aldesleukin)), to Iovance Biotherapeutics, a late-stage biotechnology company developing novel T cell-based cancer immunotherapies